Thomas Joseph Weber

Professor of Medicine

Medicine, Endocrinology, Metabolism, and Nutrition

thomas.weber2@duke.edu

ORCID iD

https://orcid.org/0000-0003-2868-2288

Duke Box 3470, Durham, NC 27710

303 Baker House, Durham, NC 27710

More About This Person

At a Glance

Credentials
1. Education

Academic Experience

Global Scholarship

Keywords

Research
1. Selected Grants
2. External Relationships

Scholarly Works

Teaching & Mentoring

Recognition

Professional Activities

Embed Profile Data

Embed Profile Data

Scholarly Works - Conferences

Burosumab Improved Serum Phosphorus, Osteomalacia, Mobility, and Fatigue in the 48-Week, Phase 2 Study in Adults with Tumor-induced Osteomalacia Syndrome

Conference JOURNAL OF BONE AND MINERAL RESEARCH · November 1, 2018 Link to item Cite

Effects of Burosumab (KRN23), a Human Monoclonal Antibody to FGF23, in Patients with Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS).

Conference JOURNAL OF BONE AND MINERAL RESEARCH · December 1, 2017 Link to item Cite

FRACTURE AND SURGICAL BURDEN IN PEDIATRIC AND ADULT PATIENTS WITH HYPOPHOSPHATASIA: RESULTS FROM PATIENT-REPORTED OUTCOME SURVEYS

Conference OSTEOPOROSIS INTERNATIONAL · February 1, 2015 Link to item Cite

Pharmacokinetics (PK) and Pharmacodynamics (PD) Following Four Monthly Doses of a Human Monoclonal Anti-FGF23 (Fibroblast Growth Factor 23) Antibody (KRN23) in Adults with X-Linked Hypophosphatemia (XLH)

Conference ENDOCRINE REVIEWS · June 1, 2014 Link to item Cite

The First Multi-Dose Trial of a Human Anti-FGF23 (Fibroblast Growth Factor 23) Antibody (KRN23) in Adults with X-Linked Hypophosphatemia (XLH)

Conference ENDOCRINE REVIEWS · June 1, 2014 Link to item Cite

Unrecognized Milk-Alkali Syndrome with Hypocalcemia Following Bisphosphonate Treatment

Conference ENDOCRINE REVIEWS · June 1, 2014 Link to item Cite

Effect of Four Monthly Doses of a Human Monoclonal Anti-FGF23 (Fibroblast Growth Factor 23) Antibody (KRN23) on Quality of Life in X-Linked Hypophosphatemia (XLH)

Conference ENDOCRINE REVIEWS · June 1, 2014 Link to item Cite

Enzyme replacement therapy (ENB-0040) in hypophosphatasia improves functional outcome and decreases TNSALP substrates in adolescents and adults

Conference Bone · May 2012 Full text Cite

Cost-Effectiveness of Oral Bisphosphonates for Osteoporosis at Different Ages and Levels of Life Expectancy.

Conference ENDOCRINE REVIEWS · June 1, 2010 Link to item Cite

Rehabilitation after Clinically-diagnosed Osteoporotic Vertebral Fracture: Results of a Pilot Study.

Conference JOURNAL OF BONE AND MINERAL RESEARCH · September 1, 2008 Link to item Cite

An Assessment of Serum Calcium and Bone Resorption Markers in Patients Transitioned from Alendronate to Denosumab.

Conference JOURNAL OF BONE AND MINERAL RESEARCH · September 1, 2008 Link to item Cite

Prevalence of hypovitaminosis D (vitamin D insufficiency and deficiency) in southern elderly osteoporotic patients.

Conference JOURNAL OF BONE AND MINERAL RESEARCH · September 1, 2003 Link to item Cite

Alendronate increases bone mineral density in male idiopathic osteoporosis.

Conference JOURNAL OF BONE AND MINERAL RESEARCH · September 1, 1999 Link to item Cite